Immune Therapeutics Adds
Former United States Assistant Surgeon
General Dr. Roscoe Moore
to Board of Directors
Orlando, FL -- August 7, 2018
-- InvestorsHub NewsWire -- Immune Therapeutics,
Inc. (OTC:
IMUN) (IMUN) ("Immune" "IMUN" or the
"Company"), a clinical late-stage
T-Cell
Activation biopharmaceutical company
focused on the development immunotherapies
for the treatment of
autoimmune and inflammatory
conditions, cancer, HIV/AIDS and animal diseases
on a global
basis, announced today that Dr.
Roscoe Moore Jr., DVM, MPH, Ph.D., DSc has joined
the
Company as
Chairman of the Board and will also maintain a position on
the Company's Scientific Advisory
Board.
"We are delighted
to welcome
Dr. Moore to IMUN
and look forward to his assistance with the clinical development of
Lodonal and MENK for the global treatment of Crohn's disease, HIV,
autoimmune disorders, and animal
conditions.
Dr. Moore's exceptional service and experience in public health,
animal sciences, the biotech sector, and regulatory affairs will
be of immense benefit to IMUN," stated Noreen Griffin,
President, and
CEO of Immune Therapeutics,
Inc.
Dr. Moore stated, "I'm very
excited about the potential of IMUN's development of Lodonal (low
dose naltrexone) for the range of immune-suppressive inflammatory
conditions that are intersecting the range of co-morbidities which
exacerbate disease progression in patients with HIV, cancer and
other significant immune characterizing diseases. The demonstration
of benefits of immuno-metabolomic relegating therapies like Lodonal
to abate the hyperactivation
of critical
cellular expression is positioned to be a promising advance
following aggregate data presented at AIDS 2018."
"Optimizing HIV Prevention
and Treatment Outcomes for Persons with Substance
Use", presented by
Anna
Deryabina,
MD at AIDS 2018 last month, highlighted NIH sponsored
research
demonstrating Naltrexone's association
with extended
viral suppression in HIV-positive patients and an improvement in CD4
recombination (video
available). The referenced CROI
presentations can be found on the CROI website. The promising CD4 recovery
data was
also
addressed in a recent HIV Plus magazine
article
discussing the disparities in addressing
neglected GI complications in HIV patients. Effective treatments,
not associated with serious adverse events, are needed to reduce
these conditions that are associated with poor antiretroviral drug
adherence, elevation of inflammatory cytokines and adverse effect
immune reconstitution. LDN was suggested as a potential treatment
for HIV- positive people experiencing GI complications such as
Crohn's disease & IBS.
Dr. Moore was a career
officer within the Commissioned Corps of the United States Public
Health Service (USPHS) and Assistant United States
Surgeon General (Rear Admiral, USPHS) within the Immediate Office
of the Secretary, Department of Health
and Human
Services (HHS). He operated as Principal
Liaison between the HHS and the ministries of
health of African countries
for the
development of
infrastructure for preventive health needs and
was integrally
involved in the
formation of the President's Emergency Program
for AIDS Relief (PEPFAR) program under
President George W. Bush, a
program which
is credited with turning the tide of the global AIDS
pandemic. He was selected as Chief
Veterinary Medical Officer, USPHS, by Surgeon General C. Everett
Koop,
and was
the Chief Epidemiologist with the Center for Devices and
Radiological Health for the
FDA. Dr.
Moore served as an Epidemic Intelligence Service Officer with the
U.S. Centers for Disease Control and Prevention
(CDC) and as the ranking
veterinarian across all uniformed services, including the armed
forces. Dr. Moore has conducted
clinical research on infectious diseases including Venezuelan equine
encephalitis, tuberculosis, listeriosis, psittacosis, malaria, and
HIV/AIDS. He has
also been involved
in the development of a sustainable infrastructure for the
surveillance of emerging and re-emerging diseases worldwide.
He has written or co-authored
over 100 publications covering a broad range of public health
issues.
Dr.
Moore has
international experience with North Africa (Morocco), North West
Africa Sub-Saharan
Africa, West Africa (Senegal, Nigeria, and Mali), Central Africa
(Central African Republic, Republic of Congo, Rwanda, and Uganda),
East Africa and Southern Africa and the countries of the Southern
African Development Community [SADC]).
Dr. Moore received his
Bachelor of Science and Doctor of Veterinary Medicine degrees
from the Tuskegee Institute; his
Master of Public Health degree in Epidemiology from the University
of Michigan; and his Doctor of Philosophy degree in Epidemiology
from the Johns Hopkins University. He was awarded the Doctor of
Science degree (Honoris Causa) by Tuskegee University
in recognition of
his distinguished career in public health.
Dr. Moore also
served as an Assistant Professor of
Oncology within the Howard University College of Medicine Cancer
Center.
Dr. Moore has worked in both
the public and private sectors to facilitate access to care for
underserved communities. He has provided expert testimony
for United
States Senate and
House of
Representatives committees of jurisdiction to
provide data-driven and fact-based information and approaches to
health care to these communities. While in both public service and the
private sector, Dr. Moore has been a respected voice
for rational
approaches to health care equity, new drug
development, and accelerate
commercialization
of new therapeutics for HIV patients and other patient
populations. Dr. Moore has been a
progenitor of Cooperative Research and Development
Agreements
to further the
development of new and innovative therapeutics.
About Immune
Therapeutics, Inc.
Immune
Therapeutics, Inc. is a late-stage
biopharmaceutical company focused on the development and
commercialization of highly innovative immunotherapies.
IMUN
is
actively
developing
T-Activation
immunotherapies to achieve immunomodulation in patients with
autoimmune and inflammatory disease, cancer and infectious
diseases.
Forward-Looking Statements
This release may contain
forward-looking statements. Actual results may differ
from those projected due to a number of risks and uncertainties,
including, but not limited to, the possibility that some or all the
matters and transactions considered by the Company may not proceed
as contemplated, and by all other matters specified in the
Company's filings with the Securities and Exchange
Commission. These statements are made
based upon current expectations that are subject to risk and
uncertainty. The Company does not
undertake to update forward-looking statements in this news release
to reflect actual results, changes in assumptions or changes in
other factors affecting such forward-looking
information. Assumptions and other
information that could cause results to differ from those set forth
in the forward-looking information can be found in the Company's
filings with the Securities and Exchange Commission
(www.sec.gov), including its recent
periodic reports.
CONTACT:
888-613-8802
http://www.immunetherapeutics.com/